Funding
Wonder Raised $650 Million to Make Dinner a Robot-Mediated IPO Problem
Wonder raised $650 million at a $9 billion valuation to scale robot kitchens, food halls, AI, and delivery. The ambition is real. So is the burn.
CircuitSmith is SiliconSnark’s founder and head writer. Originally programmed for predictive analytics, he switched to tech satire after realizing humor is the only algorithm that truly scales.
Funding
Wonder raised $650 million at a $9 billion valuation to scale robot kitchens, food halls, AI, and delivery. The ambition is real. So is the burn.
AI
Moonshot's Kimi K3 brings frontier-level AI, low API pricing, and open weights to the U.S.-China model race. The hardware bill remains enormous.
Boston Tech
Hyundai is taking full control of Waltham-based Boston Dynamics as Atlas moves from viral robot demos toward factories, manufacturing, and real work.
Policy
Europe ordered Google to open Android and Search data to rival AI services. It is a real competition shift, with privacy risks attached.
Fintech
T. Rowe Price launched TKNZ, an actively managed multi-token crypto ETP that gives investors one ticker for a volatile digital-asset basket.
Enterprise
Spectro Cloud’s $100M+ Series D funds the boring software that makes AI infrastructure governable, portable, and slightly less expensive to panic about.
Launch
OpenAI’s $230 Codex Micro turns AI-agent management into a tactile desktop ritual. It is a niche flex, but the useful kind.
Boston Tech
Cambridge startup Walden Robotics raised $300 million for trainable factory robots already working at Toyota, making Boston’s physical AI bet concrete.
Deep Dive
GPT-5.6 Sol and Claude Fable 5 excel at different work. Here is the practical guide to coding, agents, writing, price, privacy, and hype.
Funding
Mio wants to turn Slack into a place where follow-ups actually happen. A slightly unnerving AI coworker pitch with a surprisingly practical wedge.
Review
Huawei's Pura 90s Pro Max looks like a terrific camera phone with a 200MP telephoto, huge battery, and global-market weirdness that somehow adds to the charm.
Boston Tech
Apnimed's July 14 FDA filing acceptance puts its Cambridge sleep apnea pill AD109 on track for a February 28, 2027 review decision.